Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00099086
Status:
COMPLETED
Last Update Posted:
2024-01-31
First Post:
2004-12-08
Brief Title:
Docetaxel Radiation Therapy and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Sponsor:
Medical University of South Carolina
Organization:
Medical University of South Carolina
Study Overview
Official Title:
Phase I Trial of Concurrent Taxotere With Radiation Therapy and Hormonal Therapy For Clinically Localized High Risk Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase I trial is studying the side effects and best dose of docetaxel when given with radiation therapy and hormone therapy in patients with locally advanced prostate cancer
Detailed Description:
Drugs used in chemotherapy such as docetaxel work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing Radiation therapy uses high energy x-rays to kill tumor cells Docetaxel may also make tumor cells more sensitive to radiation therapy Androgens can cause the growth of prostate cancer cells Drugs such as leuprolide goserelin or bicalutamide may stop the adrenal glands from making androgens Giving chemotherapy with radiation therapy and hormone therapy may kill more tumor cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HR 11326 | OTHER | MUSC IRB | None |